10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics won a jury verdict finding Parse Biosciences willfully infringed Scale Biosciences' patents, while Parse’s invalidity challenge was rejected. The ruling strengthens TXG’s intellectual-property position, but damages, appeals and the precise commercial reach of the patents still determine the financial impact.
A jury verdict announced Aug. 28 found that Parse Biosciences willfully infringed patents owned by Scale Biosciences. The jury also rejected Parse's challenge that the patents were invalid. 10x Genomics is the publicly traded life-science technology company focused on accelerating scientific research and advancing human health that owns Scale Biosciences. The specific damages amount and exact remedies awarded remain unclear.
The case adds a legal development to 10x's operating story, which otherwise shows a business with $642.8 million of FY 2025 revenue, up 5.2% year over year. Its reported gross margin was 69.1%, while net margin was -6.8% and diluted EPS was $-0.35. Those figures frame the importance of any patent-related economic benefit: the company is generating substantial revenue but remains unprofitable.
The named companies connect through the intellectual-property dispute. 10x Genomics is the publicly traded company in the case and is the ticker in play; Scale Biosciences is identified as the patent owner; and Parse Biosciences is the defendant found to have infringed. The concrete mechanism for TXG is potential protection of technologies or market positions covered by the patents, although it remains unclear which products are implicated.
The legal outcome is not necessarily the end of the dispute. Parse could challenge the verdict or seek to limit its effect. The damages, injunction terms, appeal status and specific products involved have yet to be clarified. It also remains unknown how much of 10x's business depends on the patents, so the operating contribution cannot be quantified.
The next facts to watch are the court's damages and remedy decisions, any post-trial motions or appeal, and whether the parties disclose a settlement or licensing outcome. For 10x, subsequent company filings and operating results should show whether the verdict changes revenue, costs or competitive conditions.
The patent verdict moves the legal and competitive risk in TXG’s favor, but the financial read remains limited until damages and remedies are disclosed.
The immediate benefit is stronger intellectual-property protection for TXG, but the damages, injunction and any licensing outcome remain undisclosed. With TXG reporting $642.8M of revenue, 5.2% YoY growth and a -6.8% net margin, the verdict's earnings relevance cannot be sized until the court and the parties clarify its economic effect.
The read weakens if Parse overturns or narrows the verdict, or if the final remedy produces little or no economic benefit for TXG.
CoverageSource: PR Newswire · Published here FRI, AUG 28 · 2:38 PM ET · the only report in this recordHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The strongest bull hook is a willful-infringement finding paired with rejection of Parse’s invalidity challenge, potentially strengthening TXG’s ability to protect its commercial position.
The bear case is concrete but currently limited: no damages, injunction, licensing terms or direct TXG revenue award are provided, leaving the verdict’s financial value unquantified.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →